PERJETA and HER2+ breast cancer

Proposed mechanism of action of PERJETA

PERJETA inhibits dimerization for a more comprehensive HER2 blockade

When used together, PERJETA and Herceptin provide a dual blockade of HER2-driven signaling pathways. To learn more about the proposed mechanism of action of PERJETA, watch this video or read the overview below.

Inhibit HER2 receptor dimerization with PERJETA1

  • The pairing of HER receptors on the cell surface is referred to as dimerization2
  • HER2 dimerizes with the other members of the HER family, including HER1, HER3, and HER4 receptors3
  • HER2:HER3 dimers are believed to be the most oncogenic receptor pairing in HER2+ breast cancer.1,4,5 This pairing is thought to produce the strongest mitogenic signaling and activate two key pathways that regulate cell survival and growth3,6,7:
    • Mitogen-activated protein kinase (MAPK) cell proliferation pathway1,6,7
    • Phosphoinositide 3-kinase (PI3K) cell survival pathway1,8,9
PERJETA MOA

As seen in preclinical models: PERJETA targets a different subdomain on the HER2 receptor than Herceptin does, allowing the combination to provide a dual blockade of HER2-driven signaling pathways.1,10,11

Designed to work with Herceptin for a dual HER2 blockade, based on preclinical studies1

PERJETA MOA

Sign up for updates from Genentech

Receive emails with news and information about PERJETA and other Genentech products.

Download the Prescribing Information

View and save the full Prescribing Information for PERJETA.    

Request more information

Genentech Clinical Oncology Specialists are available to answer your questions about PERJETA.